Aarey Drugs & Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarey Drugs & Pharmaceuticals has submitted its annual disclosure under SEBI's Takeover Regulations for FY ended March 31, 2025. The promoter group, including Director Nimit Ghatalia, has confirmed that neither they nor persons acting in concert have created any encumbrance (pledge, lien, or similar charge) on their shares during the year. The filing also lists the shareholdings of the promoters and promoter group, totalling 1,27,02,443 shares, with Bina Rajesh Ghatalia (40,03,584 shares) being the largest individual holder, followed by Mihir Rajesh Ghatalia (28,35,888 shares). This is a routine annual compliance submission required from every listed company's promoters.
This is a neutral, routine compliance filing with no material impact on the stock. It reassures shareholders that promoters have not pledged any of their holdings during the year, which is mildly positive as it removes concerns over potential forced selling due to pledge calls.